LARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for LARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weekly combo may offer hope for head and neck cancer patients who can't take standard chemo
Disease control Recruiting nowThis study tests a weekly treatment of two chemotherapy drugs (carboplatin and paclitaxel) plus an immunotherapy drug (pembrolizumab) in 32 people with advanced head and neck cancer that has spread. It is for patients who cannot take the standard drug 5-fluorouracil. The goal is …
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink tumors in people with advanced head and neck cancer that has returned or spread after initial treatment. About 40 adults whose cancer worsened after first-line therapy will receive the c…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New alert system aims to cut cancer treatment delays
Knowledge-focused Recruiting nowThis study tests a new automated system to help head and neck cancer patients start radiation therapy sooner after surgery. Delays can make treatment less effective. The system uses risk predictions and automated alerts to coordinate care. About 85 adults with oral or larynx canc…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated May 17, 2026 08:05 UTC
-
Researchers hunt for clues to improve cancer treatment in patients who Can't take standard chemo
Knowledge-focused Recruiting nowThis study looks at 250 patients with head and neck cancers who cannot take the standard chemotherapy drug cisplatin. Researchers will analyze tumor tissue, saliva, stool, and blood samples to find biological markers that predict how well treatment with chemoradiotherapy and doce…
Matched conditions: LARYNX SQUAMOUS CELL CARCINOMA
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated May 17, 2026 08:04 UTC